EP Patent

EP2891654B1 — Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus)

Assigned to Shandong Xuanzhu Pharma Co Ltd · Expires 2016-06-22 · 10y expired

What this patent protects

Patent listed against Jardiance.

Drugs covered by this patent

Patent Metadata

Patent number
EP2891654B1
Jurisdiction
EP
Classification
—
Expires
2016-06-22
Drug substance claim
No
Drug product claim
No
Assignee
Shandong Xuanzhu Pharma Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.